Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
neuropsychiatrie
Erschienen in:

01.09.2014 | übersicht

Depressive und Angststörungen bei Patienten mit Epilepsie und Multipler Sklerose – eine Herausforderung für die nervenärztliche Praxis

verfasst von: Univ. Prof. Dr. Dr. Hans-Peter Kapfhammer

Erschienen in: neuropsychiatrie | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Patienten mit Epilepsie und Multipler Sklerose zeigen eine hohe Koexistenz von depressiven und Angststörungen auf. Diese Koexistenz bedeutet ein höheres subjektives Leiden, ein reduziertes Coping, mögliche negative Interferenzen mit somatischen Therapien und Rehabilitationen, eine stärkere Beeinträchtigung der Lebensqualität sowie höhere Grade an psychosozialer Behinderung. Sie schließt auch ein höheres somatisches Morbiditäts- und Mortalitätsrisiko im weiteren Verlauf ein. Die komplexen Zusammenhänge sind vorteilhaft innerhalb eines biopsychosozialen Krankheitsmodells zu integrieren. Psychologische und psychosoziale Stressoren sind eigenständig zu betrachten, aber auch in ihrer typischen neurobiologischen Vermittlung zu reflektieren. Gemeinsam geteilte pathogenetische Mechanismen von emotionaler Dysregulation einerseits und neurologischem Krankheitsprozess andererseits müssen betont werden. Vielfältige wechselseitige Interaktionen sind sowohl bei neurologischen Therapien als auch bei psychiatrischen Interventionen zu beachten.
Vorheriger Artikel Kosteneffektivität eines krankenkassengestützten Case-Management-Programms für Patienten mit affektiven Störungen
Nächster Artikel Burnout – eine sinnvolle Diagnose? Kritische Überlegungen zu einem populären Begriff
Literatur
1.
Starkstein SE, Tranel D. Neurological and psychiatric aspects of emotion. Handb Clin Neurol. 2012;106:53–74.PubMedCrossRef
2.
Kapfhammer HP. Psychische Störungen bei somatischen Krankheiten. In: Möller HJ, Laux G, Kapfhammer HP, Herausgeber. Psychiatrie, Psychosomatik und Psychotherapie. 5. Aufl. Berlin: Springer; 2014. (in Vorbereitung).
3.
Kapfhammer HP. Depressive und Angststörungen bei Patienten mit neurologischen Erkrankungen in der Perspektivität der Multimorbidität. Nervenarzt. 2014. Epub ahead of print.
4.
Trimble MR, Schmitz B. The neuropsychiatry of epilepsy. 2nd Ed. Cambridge: Cambridge University Press; 2011.CrossRef
5.
6.
Fuller-Thomson E, Brennenstuhl S. The association between depression and epilepsy in a nationally representative sample. Epilepsia. 2009;50:1051–8.PubMedCrossRef
7.
Tellez-Zenteno JF, Patten SB, Jetté N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia. 2007;48:2336–44.PubMed
8.
9.
Beyenberg S, Mitchell AJ, Schmidt D, et al. Anxiety in patients with epilepsy: systematic review and suggestions for clinical management. Epilepsy Behav. 2005;7:161–71.CrossRef
10.
Gabbs MG, Barry JJ. The link between mood disorders and epilepsy: why is it important to diagnose and treat? Adv Stud Med. 2005;5:572–8.
11.
Ettinger AB, Reed ML, Goldberg JF, Hischfeld RM. Prevalence of bipolar symptoms in epilepsy vs other chronic health disorders. Neurology. 2005;65:535–40.PubMedCrossRef
12.
Hoppe C, Elger CE. Depression in epilepsy: a critical review from a clinical perspective. Nat Rev Neurol. 2011;7:462–72.CrossRef
13.
Mula M, Jauch R, Cavanna A, et al. Interictal dysphoric disorder and periictal dysphoric symptoms in patients with epilepsy. Epilepsia. 2010;51:1139–45.PubMedCrossRef
14.
Kanner AM, Trible M, Schmitz B. Postictal affective episodes. Epilepsy. 2010;19:156–8.
15.
Kanner AM, Hesdorffer DC. Neuropsychiatric complications of epilepsy. Handb Clin Neurol. 2012;107: 461–82.PubMedCrossRef
16.
Gaitatzis A, Sisodiya SM, Sander JW. The somatic comorbidity of epilepsy: a weight but often unrecognized burden. Epilepsia. 2012;53:1282–93.PubMedCrossRef
17.
Kanner AM. Can neurobiological pathogenic mechanisms of depression facilitate the development of seizure disorders? Lancet Neurol. 2012;11:1093–102.PubMedCrossRef
18.
Petrovski S, Szoeke CEI, Jones NC, et al. Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients. Neurology. 2010;75:1015–21.PubMedCrossRef
19.
Kanner AM. Depression and epilepsy: a review of multiple facets of their close relation. Neurol Clin. 2009;27:865–80.PubMedCrossRef
20.
Cleary RA, Thompson PJ, Fox Z, Foong J. Predictors of psychiatric and seizure outcome following temporal lobe epilepsy surgery. Epilepsia 2012;53:1705–12.PubMedCrossRef
21.
de Ar aújo Filho GM, Gomes, Mazetto L, et al. Major depressive disorder as a predictor of a worse seizure outcome one year after surgery in patients with temporal lobe epilepsy and mesial temporal sclerosis. Seizure. 2012;21:619–23.PubMedCrossRef
22.
Pompili M, Baldessarini RJ. Epilepsy: risk of suicidal behavior with antiepileptic drugs. Nat Rev Neurol. 2010;6: 651–3.PubMedCrossRef
23.
Stefanello S, Marin-Leon L, Fernandes PT, et al. Suicidal thoughts in epilepsy: a community—based study in Brazil. Epilepsy Behav 2010;17:483–8.PubMedCrossRef
24.
Hesdorffer DC, Ishihara L, Mynepalli L, et al. Epilepsy, suicidality, and psychiatric disorders: a bidirectional association. Ann Neurol. 2012;72:184–91.PubMedCrossRef
25.
Sander JW. Early treatment does not seem to affect the risk of mortality in epilepsy but the presence of comorbidity may. J Neurol Neurosurg Psychiatry. 2011;82:829.PubMedCrossRef
26.
27.
Gandy M, Sharpe L, Perry KN. Psychosocial predictors of depression and anxiety in patients with epilepsy: a systematic review. J Affect Disord. 2012;140:222–32.PubMedCrossRef
28.
Hesdorffer DC, Hauser WA, Ludvigsson P, et al. Depression and attempted suicide as risk factors for incident unprovoked seizures and epilepsy. Ann Neurol. 2006;59:35–41.PubMedCrossRef
29.
Adelöw C, Andersson T, Ahlbom A, Tomson T. Hospitalization for psychiatric disorders before and after onset of unprovoked seizures/epilepsy. Neurology. 2012;78:396–401.PubMedCrossRef
30.
Kanner AM. Mood disorder and epilepsy: a neurobiologic perspective of their relationship. Dialogues Clin Neurosci. 2008;10:39–45.PubMedPubMedCentral
31.
Kanner AM. Do psychiatric comorbidities have a negative impact on the course and treatment of seizure disorders? Curr Opin Neurol. 2013;26:208–13.PubMedCrossRef
32.
Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: An analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry. 2007;15:345–54.CrossRef
33.
Schmitz B. The effects of antiepileptics on behaviour. In: Trimble MR, Schmitz B, Editors. The neuropsychiatry of epilepsy. 2nd ed. Cambridge: Cambridge University Press; 2011. pp. 133–142.CrossRef
34.
Kanner AM. The treatment of depressive disorders in epilepsy: what all neurologists should know. Epilepsia. 2013;54:3–12.PubMedCrossRef
35.
36.
Mula M, Sander JW. Suicide risk in people with epilepsy taking antiepileptic drugs. Bipolar Disord. 2013;15:622–7.PubMedCrossRef
37.
Aldenkamp AP. Antiepileptic drugs and cognitive disorders. In: Trimble MR, Schmitz B, Editors. The neuropsychiatry of epilepsy. 2nd ed. Cambridge: Cambridge University Press; 2011. pp. 153–164.CrossRef
38.
39.
Price A, Rayner L, Okon-Rocha E, et al. Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry. 2011;82:914–23.PubMedCrossRef
40.
Barry JJ, Ettinger AB, Friel P, et al. Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders. Epilepsy Behav. 2008;13:1–29.CrossRef
41.
Kerr MP, Mensah S, Besag F, et al. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia. 2011;52:2133–8.PubMedCrossRef
42.
Cardamone L, Salzberg MR, O’Brine TJ, Jones NC. Antidepressants therapy in epilepsy: can treating the comorbidities affect the underlying disorder? Br J Pharmacol. 2013;168:1531–54.PubMedCrossRefPubMedCentral
43.
Gilliam FG, Black KG, Carter J, et al. Depression and health outcomes in epilepsy: a randomized trial. Presented at the 61st annual meeting of the American Academy of Neurology; 2009: 25 April-02 May 2006; Seattle, Washington, USA.
44.
Gandy M, Sharpe L, Perry KN. Cognitive behaviour therapy for depression in people with epilepsy: A systematic review. Epilepsia. 2013;54:1734–34.CrossRef
45.
Ciechanowski P, Chaytor N, Miller J, et al. PEARLS depression treatment for individuals with epilepsy: a randomized controlled trial. Epilepsy Behav. 2010;19:225–31.PubMedCrossRef
46.
Chaytor N, Ciechanowski P, Miller JW, et al. Long-term outcomes from the PEARLS randomized trial for the treatment of depression in patients with epilepsy. Epilepsy Behav. 2011;20:545–9.PubMedCrossRef
47.
Mula M. Treatment of anxiety disorders in epilepsy: An evidence-based approach. Epilepsia. 2013;54(suppl A):13–8.PubMedCrossRef
48.
Paparrigopoulos T, Ferentinos P, Kouzoupis A, et al. The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. Int Rev Psychiatry. 2010;22:14–21.PubMedCrossRef
49.
Patten SB, Beck CA, Williams JV, Barbui C, Metz LM. Major depression in multiple sclerosis: a population-based perspective. Neurology. 2003;61:1524–27.PubMedCrossRef
50.
51.
Patten SB, Metz LM, Reimer MA. Biopsychosocial correlates of lifetime major depression in a multiple sclerosis population. Mult Scler. 2000;6:115–20.PubMedCrossRef
52.
Chwastiak L, Ehde DM, Gibbons LE, et al. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry. 2002;159:1862–8.PubMedCrossRef
53.
Fisk JD, Morehouse SA, Brown MG, et al. Hospital-based psychiatric service utilization and morbidity in multiple sclerosis. Can J Neurol Sci. 1998;25:230–5.PubMed
54.
Ghaffar O, Feinstein A. The neuropsychiatry of multiple sclerosis: a review of recent developments. Curr Opin Psychiatry. 2007;20:278–85.PubMed
55.
Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler. 2007;13:67–72.PubMedCrossRef
56.
Poder K, Ghatavi K, Fisk JD, et al. Social anxiety in a multiple sclerosis clinic population. Mult Scler. 2009;15:393–8.PubMedCrossRef
57.
Burn MN, Nawacki E, Siddique J, et al. Prospective examination of anxiety and depression before and during confirmed and pseudoexacerbations in patients with multiple sclerosis. Psychosom Med. 2013;75:76–82.CrossRef
58.
Donnchadha SÓ, Burke, Bramham J, et al. Symptom overlap in anxiety and multiple sclerosis. Mult Scler. 2013;19:1349–54.CrossRef
59.
Bombardier CH, Blake KD, Ehde DM, et al. Alcohol and drug abuse among persons with multiple sclerosis. Mult Scler. 2004;10:35–40.PubMedCrossRef
60.
61.
Jongen PJ, Ter Horst AT, Brands AM. Cognitive impairment in multiple sclerosis. Minerva Med. 2012;103:73–96.PubMed
62.
Benedict RH, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol. 2011;7:332–42.PubMedCrossRef
63.
Schumann R, Adamaszek M, Sommer N, Kirkby KC. Stress, depression and antidepressant treatment options in patients suffering from multiple sclerosis. Curr Pharm Des. 2012;18:5837–45.PubMedCrossRef
64.
Dahl OP, Stordal E, Lydersen, Midgard R. Anxiety and depression in multiple sclerosis. A comparative population-based study in Nord-Trøndelag County, Norway. Mult Scler. 2009;15:1495–501.PubMedCrossRef
65.
Wood B, van der Mei IAF, Ponsonby A-L, et al. Prevalence and concurrence of anxiety, depression and fatigue over time in multiple sclerosis. Mult Scler. 2013;19:217–24.PubMedCrossRef
66.
67.
Pompili M, Forte A, Palermo M, et al. Suicide risk in multiple sclerosis: a systematic review of current literature. J Psychosom Res. 2012;73:411–7.PubMedCrossRef
68.
Mohr DC, Hart SL, Julian L, et al. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ 2004;328:731–5.PubMedCrossRefPubMedCentral
69.
Vattakatuchery JJ, Rickards H, Cavanna AE. Pathogenic mechanisms of depression in multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2011;23:261–76.PubMedCrossRef
70.
Pujol J, Bello J, Deus J, et al. Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis. Neurology. 1997;49:1105–10.PubMedCrossRef
71.
Bakshi R, Czarnecki D, Shaikh ZA, et al. Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport. 2000;11:1153–8.PubMedCrossRef
72.
Feinstein A, Roy P, Lobaugh N, et al. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology. 2004;62:586–90.PubMedCrossRef
73.
Gold SM, Irwin MR. Depression and immunity: Inflammation and depressive symptoms in multiple sclerosis. Immunol Allergy Clin North Am. 2009;29:309–20.PubMedCrossRefPubMedCentral
74.
Kahl KG, Kruse N, Faller H, et al. Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology 2002;27:671–81.PubMedCrossRef
75.
Mohr DC, Goodkin DE, Islar J, et al. Treatment of depression is associated with suppression of nonspecific and antigen-specific TH1 responses in multiple sclerosis. Arch Neurol. 2001;58:1081–6.PubMedCrossRef
76.
Flachenecker P, Bihler I, Weber F, et al. Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler. 2004;10:165–9.PubMedCrossRef
77.
Heesen C, Nawrath L, Reich C, et al. Fatigue in multiple sclerosis: An example for cytokine-mediated sickness behaviour. J Neurol Neurosurg Psychiatry. 2006;77:34–9.PubMedCrossRefPubMedCentral
78.
Mohr DC, Pelletier D. A temporal framework for understanding the effects of stressful life events on inflammation in patients with multiple sclerosis. Brain Behav Immun. 2006;20:27–36.PubMedCrossRef
79.
Heesen C, Gold SM, Huitinga I, Reul JM. Stress and hypothalamic-pituitary-adrenal axis function in experimental autoimmune encephalomyelitis and multiple sclerosis – a review. Psychoneuroendocrinology. 2007;32:604–18.PubMedCrossRef
80.
Holsboer F, Ising M. Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol. 2010;61:81–109.PubMedCrossRef
81.
Lublin FD, Whitaker JN, Eidelman BH, et al. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology. 1996;46:12–8.PubMedCrossRef
82.
Feinstein A, O’Connor P, Feinstein K. Multiple sclerosis, interferon beta-1b and depression: A prospective investigation. J Neurol. 2002;249:815–20.PubMedCrossRef
83.
Fragoso YD, Frota ER, Lopes JS, et al. Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis. Clin Neuropharmacol. 2010;33:312–6.PubMedCrossRef
84.
Koch MW, Glazenborg A, Uyttenboogaart M, et al. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev. 2011;2:CD007295. doi: 10.1002/14651858.CD007295.pub2.PubMed
85.
Mohr DC, Boudewyn AC, Goodkin DE, et al. Comparative outcomes for individual cognitive-behavioral therapy, supportive-expressive group psychotherapy and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychology. 2001;69:942–9.CrossRef
86.
Mohr DC, Likosky W, Bertagnolli A, et al. Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis. J Consult Clin Psychol. 2000;68:356–61.PubMedCrossRef
87.
Grossman P, Kappos L, Gensicke H, et al. MS quality of life, depression, and fatigue improve after mindfulness training. Neurology. 2010;75:1141–9.PubMedCrossRefPubMedCentral
88.
Heesen C, Solari A, Giordano A, Kasper J, Köpke S. Decisions on multiple sclerosis immunotherapy: new treatment complexities urge patient engagement. J Neurol Sci. 2011;306:192–7.PubMedCrossRef
89.
Heesen C, Köpke S, Kasper J, Poettgen J, Tallner A, Mohr DC, Gold SM. Behavioral interventions in multiple sclerosis: a biopsychosocial perspective. Expert Rev Neurother. 2012;12:1089–100.PubMedCrossRef
Metadaten
Titel
Depressive und Angststörungen bei Patienten mit Epilepsie und Multipler Sklerose – eine Herausforderung für die nervenärztliche Praxis
verfasst von
Univ. Prof. Dr. Dr. Hans-Peter Kapfhammer
Publikationsdatum
01.09.2014
Verlag
Springer Vienna
Erschienen in
neuropsychiatrie / Ausgabe 3/2014
Print ISSN: 0948-6259
Elektronische ISSN: 2194-1327
DOI
https://doi.org/10.1007/s40211-014-0105-y

Weitere Artikel der Ausgabe 3/2014

Adolf Wölfli. Universum.!

  • kultur im kontext

Bericht aus dem Vorstand

  • bericht aus dem ögpp-vorstand

Bericht des Präsidenten

  • bericht aus dem ögkjp-vorstand

Religiös/Spirituelles Befinden bei psychisch Kranken III: Erste Ergebnisse einer Körper-zentrierten Achtsamkeitsmeditation in der stationären Rehabilitation

  • originalarbeit

Kosteneffektivität eines krankenkassengestützten Case-Management-Programms für Patienten mit affektiven Störungen

  • originalarbeit

Burnout – eine sinnvolle Diagnose? Kritische Überlegungen zu einem populären Begriff

  • übersicht